ストックスクリーナーアプリを入手
20.66
3.59%
-0.77
プレマーケット:
20.75
0.09
+0.44%
Viridian Therapeutics Inc (VRDN) 最新ニュース
(VRDN) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Viridian Therapeutics' Lumvoa Off to 'Stronger Start' Than Anticipated, RBC Says - finance.yahoo.com
RBC Capital Maintains Viridian Therapeutics(VRDN.US) With Buy Rating, Raises Target Price to $38 - Moomoo
RBC Capital maintains Outperform rating on Viridian Therapeutics, $38 price target - TradingView
VRDN Stock Jumps 6% After-Hours As Viridian Wins First FDA Approval - Stocktwits
Viridian Therapeutics shifts focus to launch ex... - Pluang
Viridian Therapeutics: Two Products, One Commercial Buildout (NASDAQ:VRDN) - Seeking Alpha
Viridian at Wells Fargo conference: launch gains and pipeline build By Investing.com - Investing.com Canada
Alpha Buying: 4 Biotech Stocks a Healthcare Specialist Is Buying - Benzinga
Wells Fargo Keeps Their Buy Rating on Kyverna Therapeutics, Inc. (KYTX) - theglobeandmail.com
Viridian Therapeutics to Participate in the Wells Fargo 21st Annual Healthcare Conference - Yahoo Finance
Viridian Therapeutics Inc (VRDN:UW): Stock Price, Quote and News - BNN Bloomberg
260,000 Shares in Viridian Therapeutics, Inc. $VRDN Purchased by Blue Owl Capital Holdings LP - MarketBeat
Deep Track Capital, LP Trims Viridian Therapeutics (VRDN) Stake in Strategic Rebalancing - GuruFocus
Viridian Therapeutics CLO Jennifer Tousignant sells $348,194 in shares By Investing.com - Investing.com Canada
Viridian Therapeutics CLO Jennifer Tousignant sells $348,194 in shares - Investing.com
Viridian Therapeutics (NASDAQ:VRDN) Insider Jennifer Tousignant Sells 14,212 Shares - MarketBeat
Viridian Therapeutics (VRDN) legal chief sells 14,212 shares - Stock Titan
Viridian (VRDN) Latest Quarter: Reported Results Sit Close to Expectations; Session Move: The Stock Ends Down 1.21% in Latest TradingEarnings Preview - Vinanet
Steven Cohen’s Point72 discloses Viridian stake (VRDN) - Stock Titan
Viridian Therapeutics (VRDN) Could Be 83% Undervalued On Fresh Earnings Numbers - Sahm
ETFs Investing in Viridian Therapeutics, Inc. Stocks - TradingView
Handelsbanken Fonder AB Invests $834,000 in Viridian Therapeutics, Inc. $VRDN - MarketBeat
Goldman Sachs Maintains Viridian Therapeutics(VRDN.US) With Buy Rating, Raises Target Price to $40 - Moomoo
Viridian (NASDAQ: VRDN) insider to sell 14,212 shares in August 2026 - Stock Titan
GSA Capital Partners LLP Invests $903,000 in Viridian Therapeutics, Inc. $VRDN - MarketBeat
Viridian (NASDAQ: VRDN) CMO acquires 40K shares via option - Stock Titan
93,414 Shares in Viridian Therapeutics, Inc. $VRDN Purchased by Merck & Co. Inc. - MarketBeat
1,175,906 Shares in Viridian Therapeutics, Inc. $VRDN Bought by Rice Hall James & Associates LLC - MarketBeat
Bank of America Corp DE Acquires 173,498 Shares of Viridian Therapeutics, Inc. $VRDN - MarketBeat
Stifel Maintains Viridian Therapeutics(VRDN.US) With Buy Rating, Maintains Target Price $40 - Moomoo
Viridian Therapeutics Stock Price Forecast. Should You Buy VRDN? - StockInvest.us
Paradigm BioCapital reports 6.1% Viridian (VRDN) stake and 5.3% held by offshore fund - Stock Titan
Kynam Capital group (VRDN) discloses shared power over 6.45M Viridian shares - Stock Titan
T. Rowe Price Associates (VRDN) discloses 5.2% Viridian Therapeutics ownership in 13G - Stock Titan
Deep Track group reports 3.25% Viridian Therapeutics (VRDN) ownership in latest filing - Stock Titan
Viridian Therapeutics, Inc. (1S1) Q1 2024 Earnings ReportResults, Call & Slides - TipRanks
Trading the Move, Not the Narrative: (VRDN) Edition - news.stocktradersdaily.com
Viridian Therapeutics, Inc. Stock 12‑Month Price Target Cut to $36.07, Implies 58% Upside - TradingView
Viridian Therapeutics (VRDN) Gets a Buy from Truist Financial - theglobeandmail.com
Truist Financial Maintains Viridian Therapeutics(VRDN.US) With Buy Rating, Maintains Target Price $39 - Moomoo
Analysts Have Just Cut Their Viridian Therapeutics, Inc. (NASDAQ:VRDN) Revenue Estimates By 22% - simplywall.st
Viridian Therapeutics, Inc. (NASDAQ:VRDN) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Viridian Therapeutics (VRDN) Rises 2.84% as Biotech Stock Approaches Key Resistance at $24.9Volatility Smile - careplusvn.com
Evercore Maintains Viridian Therapeutics(VRDN.US) With Buy Rating, Maintains Target Price $26 - Moomoo
Viridian Therapeutics, Inc. (NASDAQ:VRDN) Just Reported And Analysts Have Been Cutting Their Estimates - 富途牛牛
Viridian Therapeutics, Inc. (NASDAQ:VRDN) Consensus Forecasts Have Become A Little Darker Since Its Latest Report - simplywall.st
Renaissance Technologies LLC Takes $3.97 Million Position in Viridian Therapeutics, Inc. $VRDN - MarketBeat
Arrowstreet Capital Limited Partnership Has $455,000 Stock Holdings in Viridian Therapeutics, Inc. $VRDN - MarketBeat
VRDN SWOT Analysis: Financial Challenges and Growth Potential Re - GuruFocus
VRDN Maintained by RBC Capital -- Price Target Raised to $36.00 - GuruFocus
Viridian Therapeutics (NASDAQ:VRDN) Issues Quarterly Earnings Results, Misses Expectations By $0.02 EPS - MarketBeat
Viridian Therapeutics to See 'Minimal' Revenue Growth in H2, RBC Capital Markets Says - marketscreener.com
State Street Corporation (NASDAQ: VRDN) discloses 5.5% Viridian Therapeutics ownership - Stock Titan
RBC Adjusts Viridian Therapeutics PT to $36 From $35, Maintains Outperform Speculative Risk Rating - Moomoo
Truist Financial Issues Positive Forecast for Viridian Therapeutics (NASDAQ:VRDN) Stock Price - MarketBeat
A Quick Look at Today's Ratings for Viridian Therapeutics(VRDN.US), With a Forecast Between $22 to $41 - Moomoo
Viridian Therapeutics (VRDN) Climbs 2.4% to $23.05, Testing Key Resistance at $24.2Diamond Pattern - careplusvn.com
William Blair Maintains Viridian Therapeutics(VRDN.US) With Buy Rating - Moomoo
Viridian Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Wedbush Adjusts PT on Viridian Therapeutics to $41 From $43, Maintains Outperform Rating - Yahoo Finance
Earnings Flash (VRDN) Viridian Therapeutics, Inc. Reports Q2 Revenue $284,000 - marketscreener.com
Viridian Therapeutics 2Q 2026: Revenue $284K, EPS $(1.05) — 10-Q Summary - TradingView
Viridian Therapeutics Q2 net loss widens as Lumvoa launch lifts costs - TradingView
FDA‑approved TED drug and new notes reshape Viridian Therapeutics (NASDAQ: VRDN) - Stock Titan
1.11%
1.87%
大文字化:
|
ボリューム (24 時間):